CD80 and cancer: This aptamer activated T cells by impeding the CTLA-4 interaction with B7-1/B7-2, enhancing the eradication of cancer cells, and augmenting NK cells’ capacity for detecting and eliminating HLA-E-expressing cancer cells by inhibiting NKG2A.